课件：EGFR靶向治疗癌症.ppt

Current status of EGFR-targeted cancer therapy,S, Surgery; RT, Radiotherapy; CT, Chemotherapy/hormone therapy EGFR, epidermal growth factor receptor,Pre- malignancy,Localized tumors,Locally/ regionally advanced disease,Advanced/ metastatic disease,S,RT,CT + RT,CT,EGFR-targeted therapy,Potential treatment options for EGFR-targeted therapies,The concept Targeted therapy for a broad range of common solid tumors (including lung, breast, prostate, colon, ovarian, and gastric) Clinical trials Proof of concept well-tolerated therapy tumor responses in several tumor types The potential Improved outcomes in the treatment of common solid tumors,From concept to clinical trials,Tumor response,mAbs,TKIs,mAbs, monoclonal antibodies; TKIs, tyrosine kinase inhibitors,Clinical development of anticancer agents,Typical cytotoxic OBD MTD,MTD,OBD,Toxicity,Antitumor effect,Effect,Target,Dose,OBD,MTD,Novel targeted agents OBD MTD,OBD, optimal biologic dose; MTD, maximum tolerated dose Rowinsky 2000,Dose,Effect,Target,Antitumor effect,Toxicity,Clinical development of EGFR-targeted therapies,Phase I trials failed to identify the MTD of cetuximab; the OBD was identified as the dose that saturated the antibody systemic clearance rate (200 mg/m2/week) Gefitinib (IRESSA) Phase I trials did identify the MTD (700-1000 mg/day), but also showed that the OBD was 250 mg/day, as confirmed in Phase II trials Phase I trials of erlotinib identified the MTD as 150 mg/day; this is the recommended dose,Baselga et al 2000; Baselga et al 2002; Herbst et al 2002; Nakagawa et al 2003; Ranson et al 2002; Fukuoka et al 2003; Kris et al 2003; Hidalgo et al 2001,Cetuximab: approved for the treatment of advanced colorectal cancer,Partial response rate, % Disease control rate, % Median TTP, months Median survival, months,Combination* (n=218) 22.9 55.5 4.1 8.6,Monotherapy (n=111) 10.8 32.4 1.5 6.9,p value 0.007 0.001 0.001 0.48,*Cetuximab in combination with irinotecan TTP, time to progression,Cunningham et al 2003,Gefitinib (250 mg/day): approved for the treatment of advanced NSCLC,Response rate, % Disease control rate, % Median survival, months 1-year survival, % Symptom improvement*, %,IDEAL 1 (n=103) 18.4 54.4 7.6 35 40.3,IDEAL 2 (n=102) 11.8 42.2 6.5 27 43.1,*Assessed in 67 symptomatic patients in IDEAL 1 and 102 symptomatic patients in IDEAL 2,Fukuoka et al 2003; Kris et al 2003,Erlotinib: awaiting approval for the treatment of advanced NSCLC,Perez-Soler et al 2003,Other EGFR-targeted therapies under clinical development,EMD72000,h-R3,ABX-EGF,PKI-1066,CI-1033,EKB-569,mAbs,TKIs,Summary of current EGFR-targeted treatment options,To date, two EGFR-targeted therapies have been approved for the treatment of patients with advanced or metastatic CRC (cetuximab) or NSCLC (gefitinib) Approval of erlotinib for the treatment of advanced NSCLC is expected in 2004 Several other EGFR-targeted therapies are undergoing clinical development, with the majority showing some activity in a range of solid tumors,后面内容直接删除就行 资料可以编辑修改使用 资料可以编辑修改使用,主要经营：网络软件设计、图文设计制作、发布广告等 公司秉着以优质的服务对待每一位客户，做到让客户满意！,致力于数据挖掘，合同简历、论文写作、PPT设计、计划书、策划案、学习